TCRT Annual Cash & Cash Equivalents
$6.06 M
-$33.00 M-84.48%
31 December 2023
Summary:
As of January 22, 2025, TCRT annual cash & cash equivalents is $6.06 million, with the most recent change of -$33.00 million (-84.48%) on December 31, 2023. During the last 3 years, it has fallen by -$109.01 million (-94.73%). TCRT annual cash & cash equivalents is now -95.69% below its all-time high of $140.72 million, reached on December 31, 2015.TCRT Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TCRT Quarterly Cash And Cash Equivalents
$1.68 M
-$780.00 K-31.67%
30 September 2024
Summary:
As of January 22, 2025, TCRT quarterly cash and cash equivalents is $1.68 million, with the most recent change of -$780.00 thousand (-31.67%) on September 30, 2024. Over the past year, it has dropped by -$780.00 thousand (-31.67%). TCRT quarterly cash and cash equivalents is now -99.02% below its all-time high of $171.00 million, reached on March 31, 2020.TCRT Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TCRT Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -84.5% | -31.7% |
| 3 y3 years | -94.7% | -98.2% |
| 5 y5 years | -90.2% | -98.8% |
TCRT Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -92.0% | at low | -97.8% | at low |
| 5 y | 5-year | -94.7% | at low | -99.0% | at low |
| alltime | all time | -95.7% | -99.0% |
Alaunos Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $1.68 M(-31.7%) |
| June 2024 | - | $2.46 M(-40.6%) |
| Mar 2024 | - | $4.14 M(-31.6%) |
| Dec 2023 | $6.06 M(-84.5%) | $6.06 M(-49.2%) |
| Sept 2023 | - | $11.94 M(-34.8%) |
| June 2023 | - | $18.32 M(-22.0%) |
| Mar 2023 | - | $23.50 M(-39.8%) |
| Dec 2022 | $39.06 M(-48.6%) | $39.06 M(+3.3%) |
| Sept 2022 | - | $37.81 M(-37.0%) |
| June 2022 | - | $60.01 M(-12.1%) |
| Mar 2022 | - | $68.25 M(-10.3%) |
| Dec 2021 | $76.05 M(-33.9%) | $76.05 M(-17.1%) |
| Sept 2021 | - | $91.72 M(+19.5%) |
| June 2021 | - | $76.75 M(-23.3%) |
| Mar 2021 | - | $100.06 M(-13.0%) |
| Dec 2020 | $115.07 M(+44.3%) | $115.07 M(-15.1%) |
| Sept 2020 | - | $135.47 M(-11.8%) |
| June 2020 | - | $153.52 M(-10.2%) |
| Mar 2020 | - | $171.00 M(+114.4%) |
| Dec 2019 | $79.74 M(+29.2%) | $79.74 M(-9.8%) |
| Sept 2019 | - | $88.42 M(+103.0%) |
| June 2019 | - | $43.56 M(-15.4%) |
| Mar 2019 | - | $51.49 M(-16.6%) |
| Dec 2018 | $61.73 M(-13.0%) | $61.73 M(+94.6%) |
| Sept 2018 | - | $31.73 M(-21.5%) |
| June 2018 | - | $40.40 M(-20.9%) |
| Mar 2018 | - | $51.11 M(-28.0%) |
| Dec 2017 | $70.95 M(-12.5%) | $70.95 M(-15.9%) |
| Sept 2017 | - | $84.41 M(-13.2%) |
| June 2017 | - | $97.19 M(+46.3%) |
| Mar 2017 | - | $66.45 M(-18.0%) |
| Dec 2016 | $81.05 M(-42.4%) | $81.05 M(-14.4%) |
| Sept 2016 | - | $94.68 M(-13.1%) |
| June 2016 | - | $109.00 M(-12.7%) |
| Mar 2016 | - | $124.85 M(-11.3%) |
| Dec 2015 | $140.72 M(+228.8%) | $140.72 M(-14.1%) |
| Sept 2015 | - | $163.84 M(+38.2%) |
| June 2015 | - | $118.55 M(-8.6%) |
| Mar 2015 | - | $129.68 M(+203.0%) |
| Dec 2014 | $42.80 M(-37.2%) | $42.80 M(-7.2%) |
| Sept 2014 | - | $46.12 M(-13.0%) |
| June 2014 | - | $53.00 M(-12.2%) |
| Mar 2014 | - | $60.38 M(-11.5%) |
| Dec 2013 | $68.20 M(-7.0%) | $68.20 M(+188.6%) |
| Sept 2013 | - | $23.63 M(-39.3%) |
| June 2013 | - | $38.93 M(-30.0%) |
| Mar 2013 | - | $55.66 M(-24.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2012 | $73.31 M(-30.0%) | $73.31 M(-23.1%) |
| Sept 2012 | - | $95.33 M(-13.6%) |
| June 2012 | - | $110.39 M(-13.8%) |
| Mar 2012 | - | $128.01 M(+22.2%) |
| Dec 2011 | $104.71 M(+73.4%) | $104.71 M(-12.0%) |
| Sept 2011 | - | $118.93 M(-8.7%) |
| June 2011 | - | $130.28 M(+5.0%) |
| Mar 2011 | - | $124.04 M(+105.4%) |
| Dec 2010 | $60.39 M(+23.7%) | $60.39 M(-9.1%) |
| Sept 2010 | - | $66.47 M(-9.8%) |
| June 2010 | - | $73.66 M(+63.5%) |
| Mar 2010 | - | $45.04 M(-7.8%) |
| Dec 2009 | $48.84 M(+329.2%) | $48.84 M(+589.8%) |
| Sept 2009 | - | $7.08 M(+55.8%) |
| June 2009 | - | $4.54 M(-32.9%) |
| Mar 2009 | - | $6.77 M(-40.5%) |
| Dec 2008 | $11.38 M(-67.5%) | $11.38 M(-25.1%) |
| Sept 2008 | - | $15.19 M(-28.0%) |
| June 2008 | - | $21.09 M(-23.3%) |
| Mar 2008 | - | $27.49 M(-21.5%) |
| Dec 2007 | $35.03 M(+30.4%) | $35.03 M(-14.4%) |
| Sept 2007 | - | $40.94 M(-12.3%) |
| June 2007 | - | $46.69 M(-11.4%) |
| Mar 2007 | - | $52.70 M(+96.2%) |
| Dec 2006 | $26.86 M(+202.4%) | $26.86 M(-18.5%) |
| Sept 2006 | - | $32.96 M(+1.2%) |
| June 2006 | - | $32.58 M(+2918.6%) |
| Mar 2006 | - | $1.08 M(-87.8%) |
| Dec 2005 | $8.88 M(+765.0%) | $8.88 M(-17.3%) |
| Sept 2005 | - | $10.74 M(>+9900.0%) |
| June 2005 | - | $1100.00(+1000.0%) |
| Mar 2005 | - | $100.00(-100.0%) |
| Dec 2004 | $1.03 M(>+9900.0%) | $1.03 M(>+9900.0%) |
| Sept 2004 | - | $0.00(0.0%) |
| June 2004 | - | $0.00(-100.0%) |
| Mar 2004 | - | $4600.00(>+9900.0%) |
| Dec 2003 | $0.00(0.0%) | $0.00(0.0%) |
| Sept 2003 | - | $0.00(-100.0%) |
| June 2003 | - | $100.00(-99.0%) |
| Mar 2003 | - | $9900.00(>+9900.0%) |
| Dec 2002 | $0.00(-100.0%) | $0.00(0.0%) |
| Sept 2002 | - | $0.00(0.0%) |
| June 2002 | - | $0.00(-100.0%) |
| Mar 2002 | - | $5300.00(+960.0%) |
| Dec 2001 | $500.00 | $500.00(-37.5%) |
| Sept 2001 | - | $800.00(-86.4%) |
| June 2001 | - | $5900.00 |
FAQ
- What is Alaunos Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Alaunos Therapeutics?
- What is Alaunos Therapeutics annual cash & cash equivalents year-on-year change?
- What is Alaunos Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Alaunos Therapeutics?
- What is Alaunos Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Alaunos Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of TCRT is $6.06 M
What is the all time high annual cash & cash equivalents for Alaunos Therapeutics?
Alaunos Therapeutics all-time high annual cash & cash equivalents is $140.72 M
What is Alaunos Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, TCRT annual cash & cash equivalents has changed by -$33.00 M (-84.48%)
What is Alaunos Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of TCRT is $1.68 M
What is the all time high quarterly cash and cash equivalents for Alaunos Therapeutics?
Alaunos Therapeutics all-time high quarterly cash and cash equivalents is $171.00 M
What is Alaunos Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, TCRT quarterly cash and cash equivalents has changed by -$780.00 K (-31.67%)